Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1942 adjunctive therapy in mild to moderate Alzheimer's disease dementia
2021-006336-94Phase 2Active
- Sponsor
- Merck & Co.
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of MK-1942 in Alzheimer's disease (AD) (3 arms), sponsored by Merck & Co. Primary endpoint: Change from baseline in ADAS-Cog11 score at Week 12. Started Sep 2022; status: active.
02
Drugs
MK-1942
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2021-006336-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006336-94.